BioSpace News Archive

Neuronetics, Inc., a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the U.S. Food and Drug Administration 510 clearance of NeuroSite™ Coil Placement Accessory, a state-of-the-art tool that simplifies measurement and coil positioning during NeuroStar transcranial magnetic stimulation treatments.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today interim results from its Phase 1, dose escalation 065-101 study of fadraciclib (“fadra”) in patients with advanced solid tumors and lymphoma.

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, announced the appointment of Lara Meisner as chief legal officer.

Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”), announced that effective today, Marko Radic PhD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.

Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Marko Radic PhD, has joined the Nexcella Scientific Advisory Board.

Revive Therapeutics Ltd. is pleased to announce that it has signed a collaboration agreement with Attwill Medical Solutions LP (“AMS”) for the clinical and commercial development of the Company’s next-generation lyophilized formulation of Bucillamine.

Azura Ophthalmics Ltd. today announced positive topline efficacy and safety results from a Phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who could not comfortably wear their lenses as desired and who demonstrated signs of Meibomian Gland Dysfunction (MGD).

FDA encouraged the Company to accelerate enrollment of adolescent patients due to Piclidenoson’s good safety profile.

Biomerica, Inc. today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp Detect™ Stool Antigen ELISA test (K232892), a new product that is designed to detect the presence of the H. pylori bacteria, which infects approximately 35% of the U.S. population.